Web Analytics

3 Latest Announced Rounds

  • $2,500,000
    Unknown
    Services for Renewable Energy
    Nov 22nd, 2024
  • $45,000,000
    Series C
    Renewable Energy Semiconductor Manufacturing
    Nov 22nd, 2024
  • $2,500,000
    Unknown
    Services for Renewable Energy
    Nov 22nd, 2024
$1,314.20M Raised in 76 Funding Rounds in the past 7 Days - View All

Funding Round Profile

Siolta Therapeutics

start up
United States - San Carlos, California
  • 14/03/2024
  • Series C
  • $12,000,000

Siolta Therapeutics is a clinical-stage biotech company developing live biotherapeutics to improve outcomes in conditions with unmet medical needs. Our offices and laboratory are located in San Carlos, CA.


Related People

Nikole KimesFounder

Nikole Kimes United States - San Francisco, California

Dr. Nikole Kimes is Founder & Chief Executive Officer of Siolta Therapeutics, a San Francisco-based biotech company co-founded with Dr. Susan Lynch, a professor of medicine at the University of California San Francisco (UCSF), and Samir Kaul, a founding partner at Khosla Ventures. Dr. Kimes has over a decade of research experience in microbial ecology and host/microbe interactions, previously supported by a National Science Foundation Fellowship, an European Commission FP7 cooperative project (MACUMBA), and a postdoctoral scholar position at UCSF. An inventor of Siolta's technology, her research in Dr. Lynch's lab at UCSF provided the foundation from which the translational research program at Siolta Therapeutics has developed. More recently as the lead executive driving Siolta's early-stage development, Dr. Kimes is heading a talented team of scientists, blending microbiology, immunology, and bioinformatics expertise to leverage microbiome data for the improvement of patient stratification and development of precision microbial therapeutics. Siolta's vision is to transform the therapeutic landscape of inflammatory disease through the development of novel microbiome-focused strategies for the prevention and treatment of disease, starting with a focus on allergic diseases such as asthma.